Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 3/2017

01-06-2017 | ORIGINAL ARTICLE

Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study

Authors: Véronique Ferchaud-Roucher, Mikaël Croyal, Thomas Moyon, Yassine Zair, Michel Krempf, Khadija Ouguerram

Published in: Cardiovascular Drugs and Therapy | Issue 3/2017

Login to get access

Abstract

Background

Plasma high triacylglycerols and low HDL-C concentration are associated with increased cardiovascular events. Extended-release nicotinic acid (ERN) was shown to reduce plasma triacylglycerols and total cholesterol but also to markedly increase high-density lipoprotein-cholesterol (HDL-C). No data on the effect of ERN on different species of triacylglycerol, cholesteryl ester, and phospholipids are available. In this study, we applied a nontargeted lipidomic approach to investigate the plasma and lipoproteins lipids profile of hypertriglyceridemic patients treated with ERN or a placebo in order to identify new lipids markers associated with this treatment.

Methods

Eight hypertriglyceridemic patients enrolled in a crossover randomized trial with ERN for 8 weeks and treated with 2 g/day of ERN or a placebo. Ultra-performance liquid chromatography (UPLC) coupled to high-resolution mass spectrometry (HRMS) was used in mass spectrometry energy mode (HRMSE) combined with ion mobility spectrometry to characterize the plasma and very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) lipidome. The accuracy and precision of the method were validated on plasma samples.

Results

Compared to placebo, among 155 plasma lipids characterized using UPLC-ESI-HRMS, a multivariate analysis revealed a significant increase of lysophosphatidylcholine (LPC 20:5), a significant decrease of phosphatidylethanolamine (PE 16:0/22:3) and sphingomyelin (SM d18:1/22:0) and a decrease of triacylglycerol (TG 16:0/16:1/18:2) after ERN treatment. Analysis of these lipids in lipoproteins showed an increase of LPC (20:5) in HDL, a decrease of PE (16:0/22:3) in HDL and LDL, of SM (d18:1/22:0) in VLDL and LDL and of TG (16:0/16:1/18:2) in VLDL.

Conclusion

This lipidomic strategy characterized new specific lipid markers likely to be involved in the effect of ERN on cardiovascular risk opening a new strategy to analyze randomized controlled with this treatment.

Trial Registration

NCT01216956
Appendix
Available only for authorised users
Literature
1.
2.
3.
Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 1999;19:187–95.CrossRefPubMed
4.
Alaswad K, Jr O'Keefe JH, Moe RM. Combination drug therapy for dyslipidemia. Curr Atheroscler Rep. 1999;1:44–9.CrossRefPubMed
5.
6.
Lam S, Shui G. Lipidomics as a principal tool for advancing research. J Genet Genomics. 2013;40:375–90.CrossRefPubMed
7.
8.
Dunn W, Broadhurst D, Begley P, et al. And the human serum metabolome (HUSERMET) consortium. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6:1060–83.CrossRefPubMed
9.
Zhou Q, Gao B, Zhang X, Xu Y, et al. Chemical profiling of triacylglycerols and diacylglycerols in cow milk fat by ultra-performance convergence chromatography combined with a quadrupole time-of-flight mass spectrometry. Food Chem. 2014;14:3199–204.
10.
Roux A, Lison D, Junot C, et al. Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: a review. Clin Biochem. 2011;44:119–35.CrossRefPubMed
11.
Gallart-Ayala H, Courant F, Severe S, et al. Versatile lipid profiling by liquid chromatography-high resolution mass spectrometry using all ion fragmentation and polarity switching. Preliminary application for serum samples phenotyping related to canine mammary cancer. Anal Chim Acta. 2013;79:675–83.
12.
Sandra K, Pereira Ados S, Vanhoenacker G, et al. Comprehensive blood plasma lipidomics by liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr A. 2010;1217:4087–99.CrossRefPubMed
13.
Plumb R, Johnson K, Rainville P, et al. UPLC/MSE; a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun Mass Spectrom. 2006;20:1989–94.CrossRefPubMed
14.
Creskey M, Li C, Wang J, et al. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE. Vaccine. 2012;30:4762–70.CrossRefPubMed
15.
Fasciotti M, Sanvido G, Santos V, et al. Separation of isomeric disaccharides by traveling wave ion mobility mass spectrometry using CO2 as drift gas. J Mass Spectrom. 2012;47:1643–7.CrossRefPubMed
16.
Ahonen L, Fasciotti M, Gennäs G, et al. Separation of steroid isomers by ion mobility mass spectrometry. J Chromatogr A. 2013;1310:133–7.CrossRefPubMed
17.
Dear G, Munoz-Muriedas J, Beaumont C, et al. Sites of metabolic substitution: investigating metabolite structures utilising ion mobility and molecular modelling. Rapid Commun Mass Spectrom. 2010;24:3157–62.CrossRefPubMed
18.
Castro-Perez J, Roddy T, Nibbering N, et al. Localization of fatty acyl and double bond positions in phosphatidylcholines using a dual stage CID fragmentation coupled with ion mobility mass spectrometry. J Am Soc Mass Spectrom. 2011;22:1552–67.CrossRefPubMedPubMedCentral
19.
Verbeck G, Ruotolo B, Sawyer HA, et al. A fundamental introduction to ion mobility mass spectrometry applied to the analysis of biomolecules. J Biomol Tech. 2002;13:56–61.PubMedPubMedCentral
20.
Kanu A, Dwivedi P, Tam M, Matz L, et al. Ion mobility-mass spectrometry. J Mass Spectrom. 2008;43:1–22.CrossRefPubMed
21.
Blond E, Rieusset J, Alligier M, et al. Nicotinic acid affects on insulin sensitivity and hepatic lipid metabolism: an in vivo to in vitro study. “Niacin” study group. Horm Metab Res. 2014;46:390–6.CrossRefPubMed
22.
Havel RJ, Eder HA, Bragdon JH. Composition of ultracentrifugally separated lipoproteins in human serum. J Ctin Invest. 1955;34:1345–53.CrossRef
23.
Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–7.CrossRefPubMed
24.
Murphy R, Axelsen P. Mass spectrometric analysis of long-chain lipids. Mass Spectrom Rev. 2011;30:579–99.CrossRefPubMed
25.
Stokke KJ, Norum KR. Determination of 1ecithin:cholesterol acyltransferase in human blood plasma. Scand J Lab Invest. 1971;27:21–7.
26.
Castro-Perez JM, Kamphorst J, DeGroot J, Lafeber F, Goshawk J, Yu K, et al. Comprehensive LC−MSE lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J Proteome Res. 2010;9:2377–89.CrossRefPubMed
27.
Storey JD. A direct approach to false discovery rates. J R Stat Soc Ser B Stat Methodol. 2002;64:479–98.CrossRef
28.
Damen C, Isaac G, Langridge J, et al. Enhanced lipid isomer separation in human plasma using reversed-phase UPLC with ion-mobility/high-resolution MS detection. J Lipid Res. 2014;55:1772–83.CrossRefPubMedPubMedCentral
29.
Zelena E, Dunn W, Broadhurst D, et al. Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal Chem. 2009;81:1357–64.CrossRefPubMed
30.
Choi J, Kim T, Cho JY, et al. Development of lipidomic platform and phosphatidylcholine retention time index for lipid profiling of rosuvastatin treated human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;944:157–65.CrossRefPubMed
31.
Holland W, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008;29:381–402.CrossRefPubMedPubMedCentral
32.
Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol. 1999;19:1051–9.CrossRefPubMed
33.
Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004;45:1835–45.CrossRefPubMed
34.
Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoproteins kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2010;95:2727–35.CrossRefPubMedPubMedCentral
35.
Le Bloc’h J, Leray V, Chetiveaux M, Freuchet B, Magot T, Krempf M, et al. Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs. J Pharmacol Exp Ther. 2010;34:583–9.
36.
Camont L, Lhomme M, Rachid F, et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and anti-apoptotic functionalities. Atheroscler Thromb Vasc Biol. 2013;33:2715–23.CrossRef
37.
Rader D, Alexander E, Weibel G, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50:S189–94.CrossRefPubMedPubMedCentral
38.
Hara S, Shike T, Takasu N, Mizui T. Lysophosphatidylcholine promotes cholesterol efflux from mouse macrophage foam cells. Arterioscler Thromb Vasc Biol. 1997;17:1258–66.CrossRefPubMed
39.
Zhang LH, Kamanna VS, Ganji SH, et al. Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells. J Lipid Res. 2012;53:941–50.CrossRefPubMedPubMedCentral
40.
Masana L, Cabré A, Heras M, Amigó N, Correig X, Martínez-Hervás S, et al. Plana N2, Blanco-Vaca F. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis. 2015;238:213–9.CrossRefPubMed
41.
Kasumov T, Li L, Li M, Gulshan K, Kirwan JP, Liu X, Previs S, Willard B, Smith JD, McCullough A. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS One 2015;20;10:e0126910.
42.
Dong J, Liu J, Lou B, Li Z, Ye X, Wu M, et al. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice. J Lipid Res. 2006;47:1307–14.CrossRefPubMed
43.
Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest. 1996;98:1455–64.CrossRefPubMedPubMedCentral
44.
Xu XX, Tabas I. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J Biol Chem. 1991;25(266):24849–58.
45.
46.
Investigators AIM-HIGH, Boden W, Probstfield J, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.CrossRef
47.
HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12.CrossRef
48.
Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353–61.CrossRefPubMed
49.
Elam M, Hunninghake D, Davis K, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial JAMA. 2000;284:1263–70.PubMed
50.
Meyers C, Kashyap ML. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol. 2004;19:366–73.CrossRefPubMed
51.
Ganji S, Zhang L, Kamanna V, et al. Effect of niacin on lipoproteins and atherosclerosis. Futur Lipidol. 2006;1:549–57.CrossRef
Metadata
Title
Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study
Authors
Véronique Ferchaud-Roucher
Mikaël Croyal
Thomas Moyon
Yassine Zair
Michel Krempf
Khadija Ouguerram
Publication date
01-06-2017
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 3/2017
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-017-6737-y

Other articles of this Issue 3/2017

Cardiovascular Drugs and Therapy 3/2017 Go to the issue

REVIEW ARTICLE

Human iPSC-Derived Cardiomyocytes for Investigation of Disease Mechanisms and Therapeutic Strategies in Inherited Arrhythmia Syndromes: Strengths and Limitations

ORIGINAL ARTICLE

Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes

ORIGINAL ARTICLE

Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression

ORIGINAL ARTICLE

Primary Care Physician Perspectives on Barriers to Statin Treatment

EDITORIAL

Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line

ORIGINAL ARTICLE

Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits